Clinical Trials Directory

Trials / Conditions / Recurrent Thyroid Gland Carcinoma

Recurrent Thyroid Gland Carcinoma

14 registered clinical trials studyying Recurrent Thyroid Gland Carcinoma.

StatusTrialSponsorPhase
TerminatedRadiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule
NCT05003856
M.D. Anderson Cancer CenterN/A
Active Not RecruitingSelpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
NCT04759911
M.D. Anderson Cancer CenterPhase 2
Active Not RecruitingTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter
NCT04284774
National Cancer Institute (NCI)Phase 2
Active Not RecruitingTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph
NCT02465060
National Cancer Institute (NCI)Phase 2
CompletedIodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
NCT02393690
Academic and Community Cancer Research UnitedPhase 2
Active Not RecruitingTrametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
NCT02152995
National Cancer Institute (NCI)Phase 2
CompletedCabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
NCT01811212
National Cancer Institute (NCI)Phase 2
CompletedCabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
NCT01709435
National Cancer Institute (NCI)Phase 1
CompletedRomidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun
NCT01638533
National Cancer Institute (NCI)Phase 1
Active Not RecruitingBevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With
NCT01552434
M.D. Anderson Cancer CenterPhase 1
CompletedAflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radio
NCT00729157
National Cancer Institute (NCI)Phase 2
CompletedPazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
NCT00625846
National Cancer Institute (NCI)Phase 2
CompletedSelumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
NCT00559949
National Cancer Institute (NCI)Phase 2
CompletedSunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be R
NCT00381641
National Cancer Institute (NCI)Phase 2